Across TCGA pan-cancer cohorts, MIR1295A RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MIR1295A’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR1295A RNA is repressed in tumor relative to normal tissue. In most cancer types MIR1295A is over-expressed in tumor, although a few such as BRCA and CHOL show the opposite, repressed pattern.

BRCA, CHOL, and LIHC are the cancer types where MIR1295A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR1295A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.388	<.001	6	view →
CHOL	All	All	−2.363	<.001	2	view →
LIHC	Male	All	+0.705	.049	1	view →
LUSC	Male	II,III,IV	−0.476	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIR1295A RNA expression & survival · all MIR1295A data types